Nebenwirkungen · Juluca
Juluca 50 mg/25 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 20
HOS-138751 · Präparat HOS-098240
Dolutegravir or rilpivirine have been associated with increases in serum creatinine occurring in the first week of treatment when administered with other antiretroviral medicinal products. Increases in serum creatinine occurred within the first four weeks of treatment with dolutegravir/rilpivirine and remained stable through 148 weeks. A mean change from baseline of 9.86 mol/L (SD 10.4 mol/L) was observed after 148 weeks treatment. These changes are related to inhibition of active transport, and are not considered to be clinically relevant as they do not reflect a change in glomerular filtration rate.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:39:00Z · SHA-256 0933317665b752128ea731fe5d180ec3ebff8bd69929c361b4010ae11184c9c5 · Passage 415deecbfe427f8e19aaccbcd9d53b26f3771abe04017097c359c15f399d425e · Zeichen 5461–6071 im Abschnitt